secur
graft
pandem
readi
cryopreserv
biolog
blood
marrow
transplant
doi
http
doiphon
fax
secretari
email
bhagirathbhairdholaria
vumcorg
allogen
hematopoiet
cell
transplant
allohct
unrel
donor
involv
complex
interplay
multipl
organ
work
togeth
success
deliveri
stem
cell
graft
recipi
histor
cryopreserv
stem
cell
graft
done
small
fraction
allohct
due
concern
around
neg
impact
freez
thaw
viabil
hematopoiet
stem
cell
function
donor
lymphocyt
previou
retrospect
studi
compar
allohct
outcom
cryopreserv
versu
freshli
infus
peripher
blood
stem
cell
pbsc
graft
match
donor
shown
compar
surviv
outcom
margin
delay
neutrophil
platelet
engraft
cryopreserv
studi
shown
increas
risk
graftversushost
diseas
gvhd
least
match
sibl
donor
result
consist
match
unrel
donor
graft
absenc
prospect
random
studi
question
cryopreserv
graft
replac
freshlyinfus
graft
allohct
without
compromis
outcom
current
studi
show
compar
surviv
outcom
cryopreserv
n
propensitymatch
freshli
infus
graft
n
patient
variou
hematolog
malign
donor
type
suggest
decreas
risk
chronic
gvhd
lower
diseasefre
surviv
among
recipi
cryopreserv
graft
studi
detect
differ
overal
surviv
howev
sampl
size
might
limit
factor
previou
studi
shown
reduc
viabil
prolifer
cytokin
releas
capac
donor
lymphocyt
cryopreserv
impair
alloreact
graft
cell
due
cryopreserv
may
reason
reduc
chronic
gvhd
incid
higher
risk
diseas
relaps
natur
killer
nk
cell
appear
low
toler
freez
thaw
process
compar
mononuclear
cell
becom
import
given
delay
nkcell
reconstitutionmatur
seen
ptci
could
anoth
potenti
explan
increas
risk
diseas
relaps
cryopreserv
graft
need
studi
system
type
cryopreserv
media
also
appear
impact
cell
viabil
need
valid
cryopreserv
becom
routin
practic
futur
author
correctli
point
sever
limit
analysi
importantli
lack
inform
reason
cryopreserv
individu
patient
addit
immun
reconstitut
surrog
marker
cell
viabil
cryopreserv
influenc
cryopreserv
strategi
requir
studi
emerg
existenti
threat
human
go
last
impact
healthcar
system
travel
restrict
donor
avail
blood
product
shortag
strain
health
care
system
secondari
pandem
forc
us
reevalu
current
model
allohct
face
challeng
nation
marrow
donor
program
nmdp
european
societi
blood
marrow
transplant
strongli
recommend
cryopreserv
unrel
donor
graft
center
move
cryopreserv
relat
donor
graft
thu
welcom
data
cryopreserv
graft
sever
advantag
cryopreserv
apart
logist
simplic
cryopreserv
allow
assur
adequ
cell
dose
avail
older
lower
bodi
mass
relat
donor
condit
regimen
start
allow
addit
period
donor
monitor
case
exposur
communic
diseas
graft
infus
cryopreserv
may
facilit
alloc
fraction
cell
storag
futur
donor
lymphocyt
infus
assum
prespecifi
cell
count
threshold
met
one
also
note
pitfal
routin
cryopreserv
stem
cell
graft
largest
uncertainti
pertain
whether
delay
cryopreserv
signific
travel
detriment
unrel
donor
graft
courier
chaperon
unrel
graft
may
face
unpredict
delay
due
transport
challeng
graft
chaperon
courier
studi
includ
unrel
graft
separ
analyz
day
delay
cryopreserv
reduc
viabil
umbil
cord
one
studi
show
signific
engraft
failur
failur
occur
patient
receiv
unrel
donor
pbsc
oppos
receiv
relat
pbsc
graft
apart
risk
infus
reaction
dimethyl
sulfoxid
potenti
loss
cell
dose
wash
routin
cryopreserv
costli
may
put
strain
stem
cell
process
facil
invari
cryopreserv
graft
infus
due
recipi
relat
issu
leav
donor
expos
unnecessari
health
risk
registrybas
analysi
suggest
rel
safeti
routin
cryopreserv
set
ptci
prospect
registri
studi
appropri
follow
would
best
establish
safeti
detect
pitfal
shortcom
cryopreserv
new
recommend
nmdp
cryopreserv
unrel
donor
due
crise
serv
good
stage
prospect
studi
thank
author
time
studi
result
rapidli
applic
current
era
import
adapt
world
ration
datadriven
lesson
learn
strengthen
abil
protect
patient
donor
similar
threat
futur
